Results 31 to 40 of about 12,232 (185)

PCSK9 inhibitors for LDL lowering [PDF]

Trends in Cardiovascular Medicine, 2015
In 2003, families were described with a rare, autosomal dominant form of familial hypercholesterolemia due to gain-of-function mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9) [1]. Subsequent studies demonstrated that PCSK9 is secreted from liver and accelerates degradation of LDL receptors [2,3].
openaire   +2 more sources

Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study

Brain and Behavior
Background In addition to lowering cholesterol levels, the proprotein convertase subtilis kexin 9 (PCSK9) inhibitor has a variety of effects, including anti‐neuroapoptosis.
Qiang Huang, Qin Zhang, Bei Cao
doaj   +1 more source

The Evolving Future of PCSK9 Inhibitors

Journal of the American College of Cardiology, 2018
Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies that target PCSK9 lower LDL cholesterol (LDL-C) levels by 55% to 72% in different high-risk patient groups.
Robert S, Rosenson, Robert A, Hegele, Sergio, Fazio, Christopher P, Cannon   +3 more
openaire   +2 more sources

Recent advances in the construction of humanized animal models and applications in translational medicine

Animal Models and Experimental Medicine, EarlyView.
Substantial advances have been achieved in the development of humanized mouse models, which have proven highly valuable in evaluating cancer immunotherapies and elucidating the mechanisms of infectious diseases. There is now a growing shift in research toward larger animal models—such as pigs—that offer greater physiological similarity to humans ...
Yanan Lyu, Yong‐Guang Yang, Zheng Hu
wiley   +1 more source

PCSK9 Modulates Macrophage Polarization-Mediated Ventricular Remodeling after Myocardial Infarction

Journal of Immunology Research, 2022
Background and Aims. An increasing number of high-risk patients with coronary heart disease (similar to acute myocardial infarction (AMI)) are using PCSK9 inhibitors.
Feifei Wang, Min Li, Aidong Zhang, Hairui Li, Can Jiang, Jun Guo   +5 more
doaj   +1 more source

PCSK9 deficiency alters brain lipid composition without affecting brain development and function

Frontiers in Molecular Neuroscience, 2023
PCSK9 induces lysosomal degradation of the low-density lipoprotein (LDL) receptor (LDLR) in the liver, hereby preventing removal of LDL cholesterol from the circulation.
Angela Pärn, Ditte Olsen, Jürgen Tuvikene, Jürgen Tuvikene, Mathias Kaas, Ekaterina Borisova, Ekaterina Borisova, Mesut Bilgin, Mie Elhauge, Joachim Vilstrup, Joachim Vilstrup, Peder Madsen, Peder Madsen, Mateusz C. Ambrozkiewicz, Roman U. Goz, Tõnis Timmusk, Tõnis Timmusk, Victor Tarabykin, Victor Tarabykin, Camilla Gustafsen, Camilla Gustafsen, Simon Glerup, Simon Glerup   +22 more
doaj   +1 more source

Food‐grade proteins, lipids, and fibers as potential tools to ameliorate cardiovascular disorders: A review

Food Biomacromolecules, EarlyView.
Abstract Cardiovascular diseases (CVDs) remain the leading cause of global mortality, necessitating effective preventive and adjunct therapeutic strategies beyond conventional pharmacological interventions. Although previous reviews have focused on individual nutrients or dietary patterns, this review provides a mechanism‐based, integrative perspective
Sridevi Shanmugam, Rukaiah Fatma Begum, Nirenjen Shanmugasundaram, Bhupendra Gopalbhai Prajapati, Suresh Ankul Singh, Pavithra Nagenthran, Sudarshan Singh, Kesarla Rajesh   +7 more
wiley   +1 more source

PCSK9: NEW VICTORY AND HORIZONS

Атеросклероз, 2018
The review presents the latest data from the world scientific literature of clinical studies of inhibitors protoprotein convertasesubtilisin/kexin 9 type (PCSK9).
M. O. Smolina, K. S. Benimetskaya, Yu. I. Ragino, M. I. Voevoda   +3 more
doaj   +1 more source

Investigating the potential impact of PCSK9-inhibitors on mood disorders using eQTL-based Mendelian randomization

PLoS ONE, 2022
Prescription of PCSK9-inhibitors has increased in recent years but not much is known about its off-target effects. PCSK9-expression is evident in non-hepatic tissues, notably the brain, and genetic variation in the PCSK9 locus has recently been shown to ...
Alisha Aman, Eric A. W. Slob, Joey Ward, Breda Cullen, Nicholas Graham, Donald M. Lyall, Naveed Sattar, Rona J. Strawbridge   +7 more
doaj   +2 more sources

PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis

BMC Musculoskeletal Disorders
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent an effective strategy for reducing cardiovascular disease risk. Yet, PCSK9’s impact on osteoporosis remains unclear.
Ding-Qiang Chen, Wen-Bin Xu, Ke-Yi Xiao, Zhi-Qiang Que, Jin-Yi Feng, Nai-Kun Sun, Di-Xin Cai, Gang Rui   +7 more
doaj   +1 more source